Botulinum Toxin for Spasticity
Botulinum toxin (BoNT) injection is the gold standard for the treatment of focal and multifocal spasticity, with Grade A evidence supporting its use in both upper and lower limb post-stroke spasticity. Understanding the different formulations, proper muscle selection based on spasticity patterns, injection guidance techniques, and — critically — the integration of botulinum toxin with rehabilitation therapy is essential for optimal patient outcomes. Injection without concurrent rehabilitation is a missed opportunity, as the toxin creates a time-limited window for neuroplastic change that must be exploited with targeted therapy.
Bottom Line
- Grade A evidence: AAN practice guidelines provide Grade A recommendation for botulinum toxin in both upper and lower limb post-stroke spasticity.
- Formulations are NOT interchangeable: OnabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), and incobotulinumtoxinA (Xeomin) use different unit systems with approximate conversion ratios of Botox:Dysport = 1:2.5–3 and Xeomin:Botox = 1:1.
- Pattern-based injection targeting: Accurate identification of spasticity patterns and selection of the correct muscles is the most important factor in treatment success.
- Injection guidance is essential: Ultrasound, EMG, or electrical stimulation improves accuracy; blind injection has unacceptably high rates of misplacement.
- Window of opportunity: BoNT creates a 3–4 month window of reduced tone that MUST be combined with stretching, casting, splinting, and task-specific training for optimal functional outcomes.
- Dose and timing: Start conservative and titrate up; re-inject every 12–16 weeks; avoid intervals shorter than 12 weeks to minimize antibody formation risk.
Mechanism of Action
Botulinum toxin is a neurotoxin produced by Clostridium botulinum that produces dose-dependent muscle weakening through a well-characterized molecular mechanism.
Molecular Mechanism
- Binding: The heavy chain of the toxin binds to receptors on the presynaptic cholinergic nerve terminal at the neuromuscular junction (NMJ)
- Internalization: The toxin is internalized into the nerve terminal via receptor-mediated endocytosis
- Cleavage: The light chain acts as a zinc-dependent endoprotease that cleaves SNARE proteins (synaptosomal-associated protein 25 [SNAP-25] for type A; VAMP/synaptobrevin for type B), which are essential for acetylcholine vesicle fusion and release
- Block: Acetylcholine release is blocked, producing chemical denervation and dose-dependent muscle weakening
- Antispasticity effect: Beyond NMJ blockade, BoNT also reduces muscle spindle afferent activity by affecting intrafusal muscle fibers (gamma motor neuron terminals), directly modulating the afferent limb of the stretch reflex
- Recovery: New nerve terminals sprout and form functional NMJs over 3–4 months, restoring muscle function — this is why repeat injection is needed
Botulinum Toxin Formulations
| Formulation | Brand Name | Serotype | SNARE Target | Complexing Proteins | Key Features |
|---|---|---|---|---|---|
| OnabotulinumtoxinA | Botox | Type A | SNAP-25 | Yes (900 kDa complex) | Most extensively studied; reference standard; requires refrigeration after reconstitution |
| AbobotulinumtoxinA | Dysport | Type A | SNAP-25 | Yes (500–900 kDa complex) | Different unit system from Botox; may have wider diffusion field; FDA-approved for adult upper and lower limb spasticity |
| IncobotulinumtoxinA | Xeomin | Type A | SNAP-25 | No (150 kDa pure toxin) | Free of complexing proteins; theoretically lower immunogenicity; room temperature storage; similar potency to Botox unit-for-unit |
| RimabotulinumtoxinB | Myobloc | Type B | VAMP/synaptobrevin | Yes | Different serotype; useful for patients with type A antibody resistance; more pain at injection; higher rate of autonomic side effects (dry mouth) |
Critical: Units Are NOT Interchangeable
- Botox, Dysport, and Xeomin units are defined differently based on each manufacturer’s proprietary mouse LD50 assay
- Approximate conversion ratios:
- Botox : Dysport = 1 : 2.5–3 (i.e., 100 U Botox ≈ 250–300 U Dysport)
- Xeomin : Botox = approximately 1 : 1 (i.e., 100 U Xeomin ≈ 100 U Botox)
- These are approximate ratios — individual dose titration is always necessary
- Switching formulations requires careful dose adjustment
- Myobloc units are completely different: 5,000 U Myobloc ≈ 100 U Botox (very rough estimate)
Evidence Base
Key Evidence for BoNT in Spasticity
- AAN Practice Guideline (Simpson et al., 2016): Grade A recommendation for BoNT in upper limb spasticity and lower limb spasticity in adults
- Upper limb: Multiple RCTs (Brashear et al. 2002, Simpson et al. 2009, Gracies et al. 2015) demonstrate significant reduction in MAS scores and improvement in goal attainment
- Lower limb: RCTs demonstrate significant improvement in ankle spasticity (equinovarus), gait velocity, and goal attainment
- Outcome measures: BoNT consistently reduces tone (MAS) and achieves patient-centered goals (GAS); evidence for improvement in broader functional measures (e.g., Barthel Index) is less consistent, likely because functional outcomes depend on many factors beyond spasticity
- Dose-response: Higher doses generally produce greater tone reduction, but also greater weakness; optimal dosing balances tone reduction with preservation of voluntary strength
Upper Limb Spasticity Patterns & Injection Targets
Upper limb spasticity typically follows recognizable patterns that reflect the dominance of flexor and pronator muscle groups. Accurate pattern identification is essential for selecting the correct muscles to inject.
| Pattern | Target Muscles | Typical Botox Dose (U) | Clinical Notes |
|---|---|---|---|
| Shoulder adduction / internal rotation | Pectoralis major Subscapularis Teres major Latissimus dorsi |
75–150 50–100 50–75 50–100 |
Common pattern causing difficulty with dressing and hygiene; subscapularis is deep — requires ultrasound guidance; pectoralis major often the primary contributor |
| Elbow flexion | Biceps brachii Brachialis Brachioradialis |
100–200 50–100 50–75 |
Very common; brachialis is deep to biceps and often underinjected; brachioradialis contributes to flexion in pronated position |
| Forearm pronation | Pronator teres Pronator quadratus |
50–75 25–50 |
Pronation limits functional use of the hand; pronator teres is the primary contributor; pronator quadratus is deep in the distal forearm |
| Wrist flexion | Flexor carpi radialis (FCR) Flexor carpi ulnaris (FCU) |
50–100 50–100 |
FCR and FCU are the primary wrist flexors; FCR is usually the dominant contributor; wrist flexion position limits grip and release |
| Finger flexion (clenched fist) | Flexor digitorum superficialis (FDS) Flexor digitorum profundus (FDP) |
50–100 50–100 |
FDS controls PIP flexion; FDP controls DIP flexion; clenched fist causes palmar skin maceration, nail injury, hygiene problems; distinguish from contracture (requires different treatment) |
| Thumb-in-palm | Flexor pollicis longus Adductor pollicis Flexor pollicis brevis Opponens pollicis |
25–50 10–25 10–20 10–20 |
Multiple muscles contribute; adductor pollicis and flexor pollicis longus are most important; intrinsic hand muscles are small — use low doses and precise guidance |
| Intrinsic-plus hand | Lumbricals Interossei |
5–15 per muscle | MCP flexion with IP extension; less common than extrinsic flexor spasticity; requires very careful dosing to avoid weakening grip |
Lower Limb Spasticity Patterns & Injection Targets
| Pattern | Target Muscles | Typical Botox Dose (U) | Clinical Notes |
|---|---|---|---|
| Hip adduction (scissoring) | Adductor longus Adductor magnus Gracilis |
75–200 75–200 50–100 |
Limits perineal hygiene, catheterization, ambulation; adductor longus is the primary target; often combined with phenol obturator nerve block for large muscles |
| Hip flexion | Iliopsoas Rectus femoris |
100–200 100–200 |
Impairs standing posture and gait; iliopsoas is deep — requires ultrasound guidance; rectus femoris also contributes to knee extension (consider impact on gait) |
| Knee flexion | Medial hamstrings (semitendinosus, semimembranosus) Lateral hamstrings (biceps femoris) |
100–200 100–200 |
Crouched gait pattern; large muscles requiring high doses; consider whether patient uses hamstring spasticity for knee stability before treating |
| Knee extension (stiff knee gait) | Rectus femoris Vastus intermedius |
100–200 100–200 |
Knee hyperextension in stance and poor knee flexion in swing; rectus femoris is the primary culprit in stiff-knee gait (use EMG to confirm) |
| Equinovarus foot | Gastrocnemius (medial & lateral heads) Soleus Tibialis posterior Flexor digitorum longus |
75–200 75–150 50–100 50–75 |
Most common lower limb pattern; equinus (plantar flexion) from gastrocnemius/soleus; varus (inversion) from tibialis posterior; toe curling from FDL; key to improving gait safety |
| Striatal toe (hitchhiker toe) | Extensor hallucis longus (EHL) | 25–75 | Involuntary great toe extension (dystonic posture); interferes with shoe fitting and gait; also consider flexor hallucis longus if there is a paradoxical co-contraction pattern |
| Toe flexion (curling) | Flexor digitorum longus Flexor digitorum brevis Flexor hallucis longus |
50–75 25–50 25–50 |
Painful toe clawing; difficulty with shoe wearing; pressure ulcers on toe tips; intrinsic foot muscles may also contribute |
Injection Guidance Techniques
Accurate muscle targeting is essential for treatment efficacy and safety. Blind (landmark-based) injection has been shown to have unacceptably high rates of inaccurate needle placement, particularly for deeper muscles.
| Technique | Method | Advantages | Limitations |
|---|---|---|---|
| Ultrasound (US) | Real-time B-mode imaging to visualize target muscle, needle tip, and surrounding structures | Increasingly preferred method; real-time visualization; no pain from stimulation; identifies neurovascular structures; confirms needle in correct muscle; no additional equipment needed beyond US probe | Requires training; image quality varies with body habitus; does not confirm muscle activity |
| Electromyography (EMG) | Hollow, Teflon-coated needle records electrical activity from the target muscle; listen for spontaneous and voluntary activity | Confirms needle is in active (spastic) muscle; best for deep/small muscles where US visualization is challenging | Requires EMG equipment; patient discomfort from stimulation; does not visualize anatomy |
| Electrical stimulation (E-stim) | Low-current stimulation through the injection needle produces visible/palpable contraction of the target muscle | Confirms motor point location; provides visual confirmation of correct muscle via observed movement | Painful for some patients; may be difficult in severely paretic muscles; requires stimulator |
| Anatomical landmarks (blind) | Needle placement based on surface anatomy alone | No additional equipment; fastest technique | Not recommended as sole guidance: studies show 30–60% inaccurate placement for some muscles; higher for deep muscles |
Dosing Principles
Practical Dosing Guidelines
- Start conservative: Begin with lower doses, especially in treatment-naive patients, and titrate upward at subsequent sessions based on response
- Maximum total dose per session (onabotulinumtoxinA): Typically 400–600 U in most clinical practice; some experienced centers use up to 800 U with appropriate monitoring; higher total doses carry greater risk of systemic weakness
- Body weight considerations: Lower total doses in smaller patients; particular caution in patients <50 kg
- Distribution across muscles: Prioritize the muscles contributing most to the functional problem; it is better to adequately dose the most important muscles than to spread a limited dose thinly across many muscles
- Dilution: Standard reconstitution for Botox is 100 U in 1–2 mL saline; higher dilution may increase diffusion radius (useful for large muscles); lower dilution provides more precise targeting for small muscles
- Number of injection sites per muscle: Multiple sites (2–4) within a large muscle improve distribution and efficacy; single site may suffice for small muscles
Time Course of Effect
| Parameter | Timeline | Clinical Implication |
|---|---|---|
| Onset | 3–7 days | Counsel patients that effect is not immediate; some may notice changes at 2–3 days, full effect takes longer |
| Peak effect | 2–6 weeks | Schedule rehabilitation therapy and follow-up assessment during this window to maximize benefit |
| Duration | 3–4 months (typical) | Some patients experience shorter or longer duration; may vary by muscle and dose |
| Re-injection interval | Every 12–16 weeks | Intervals <12 weeks may increase antibody formation risk; some patients can extend to 16–20 weeks with stable response |
Adverse Effects
| Adverse Effect | Frequency | Mechanism | Management |
|---|---|---|---|
| Excessive weakness | Common | Dose-related; direct effect on injected muscle; may also reflect diffusion to adjacent muscles | Reduce dose at next injection; improve injection accuracy; reassess muscle selection |
| Injection site pain | Common | Needle trauma; volume of injectate | Use smaller gauge needles; topical anesthetic; ice application |
| Flu-like symptoms | Occasional | Likely immune-mediated | Self-limiting; symptomatic treatment |
| Dysphagia | Rare (cervical injections) | Diffusion of toxin to pharyngeal/laryngeal muscles when injecting neck muscles | Avoid high doses in cervical muscles; use precise guidance; monitor swallowing after cervical injections |
| Respiratory compromise | Very rare | Bilateral phrenic nerve involvement; systemic spread | Avoid bilateral diaphragm/intercostal injection; caution in patients with pre-existing respiratory compromise (NMD, high SCI) |
| Antibody formation | ~1–5% with chronic use | Neutralizing antibodies against toxin light chain; risk increased with higher doses and shorter intervals | Suspect when previously effective treatment becomes ineffective (secondary non-response); switch serotype (Myobloc) or formulation (Xeomin has theoretical advantage due to lack of complexing proteins) |
Secondary Non-Response (Antibody-Mediated Resistance)
- Definition: Loss of previously established therapeutic response due to development of neutralizing antibodies
- Risk factors: Higher total doses per session, shorter injection intervals (<12 weeks), booster injections, and higher cumulative lifetime dose
- Assessment: Frontalis test (inject small dose into frontalis muscle — if no eyebrow elevation effect, antibodies are likely present); confirmatory antibody testing available but not widely standardized
- Management: Switch to a different serotype (rimabotulinumtoxinB / Myobloc); some clinicians switch to incobotulinumtoxinA (Xeomin) first, given its lack of complexing proteins, though evidence for overcoming existing antibodies is limited
- Prevention: Use the lowest effective dose; maintain intervals ≥12 weeks; avoid booster injections
Integration with Rehabilitation
This is arguably the most important aspect of botulinum toxin treatment for spasticity. Injection alone, without concurrent rehabilitation, produces suboptimal outcomes.
The “Window of Opportunity” Approach
- Concept: Botulinum toxin creates a time-limited (3–4 month) window of reduced spasticity during which the patient can participate more effectively in targeted rehabilitation
- Stretching and range of motion: Begin or intensify stretching program within 1 week of injection; sustained stretch during the period of reduced tone can prevent contracture and improve ROM
- Serial casting: Apply within 1–2 weeks of injection (after onset of effect); sequential casts at progressively improved joint angles; particularly effective for ankle equinus combined with gastrocnemius/soleus injection
- Splinting: Night splints or resting splints to maintain gains achieved through stretching and casting; custom-molded for optimal fit
- Task-specific training: If the treatment goal is improved active function (e.g., reaching, grasping, walking), intensive task-specific practice during the window of reduced tone is essential; this is when neuroplastic change can be maximized
- Functional electrical stimulation: FES of antagonist muscles combined with BoNT of agonists may enhance the effect through reciprocal inhibition and active muscle strengthening
- Evidence: Studies consistently show that BoNT combined with rehabilitation produces better outcomes than either intervention alone
Special Considerations
Spasticity vs. Contracture
Distinguishing Spasticity from Contracture
- Spasticity: Velocity-dependent; resistance to passive stretch decreases at slow velocity; affected by positioning and arousal state; reversible with treatment
- Contracture: Fixed shortening of muscle, tendon, or joint capsule; resistance is the same regardless of velocity; not improved by antispasticity medications
- Modified Tardieu Scale: The difference between R2 (slow passive ROM) and R1 (angle of catch at fast stretch) indicates the neural (spastic) component; if R1 = R2, the limitation is entirely due to contracture
- Clinical significance: Botulinum toxin will NOT improve fixed contracture — only the dynamic (spastic) component responds; patients with predominantly contracture need surgical intervention (tendon lengthening)
- Mixed presentations: Many patients have both spasticity and contracture; BoNT addresses the spastic component, creating an opportunity for stretching/casting to address early contracture
Spasticity in Multiple Sclerosis
- BoNT is effective for focal MS spasticity (hip adductors, plantar flexors)
- Lower doses may be appropriate given the potential for underlying weakness
- Careful attention to functional spasticity — many MS patients use extensor spasticity for standing and transfers
Spasticity in Spinal Cord Injury
- BoNT useful for focal patterns; intrathecal baclofen preferred for severe generalized spasticity
- Bladder detrusor injection for neurogenic detrusor overactivity (separate indication with strong evidence)
Summary: Treatment Protocol
Practical Protocol for BoNT Spasticity Treatment
- Pre-injection: Define goals (GAS); identify spasticity patterns; examine for contracture; address aggravating factors; plan rehabilitation program to begin after injection
- Injection day: Select muscles based on pattern analysis; use guidance (ultrasound preferred); inject with appropriate dose; document muscles, doses, and guidance used
- Week 1–2: Onset of effect; begin/intensify stretching program; initiate serial casting if planned
- Week 2–6: Peak effect; intensive rehabilitation window; task-specific training; splinting to maintain gains
- Week 6–12: Effect waning; maintain stretching and splinting; assess goal attainment
- Week 12–16: Re-inject if goals not met or maintained; adjust dose and muscle selection based on previous response; plan next rehabilitation cycle
References
- Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86(19):1818–1826.
- Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med. 2002;347(6):395–400.
- Gracies JM, Brashear A, Jech R, et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015;14(10):992–1001.
- Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13–25.
- Picelli A, Lobba D, Midiri A, et al. Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil. 2014;28(3):232–242.
- Esquenazi A, Albanese A, Chancellor MB, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013;67:115–128.
- Hesse S, Mach H, Frohlich S, et al. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. Am J Phys Med Rehabil. 2012;91(7):609–616.
- Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines. 2nd ed. London: RCP; 2018.
- Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005;63(1):180–185.
- Olver J, Esquenazi A, Fung VS, et al. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol. 2010;17(Suppl 2):57–73.
- Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981–990.
- Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008;115(4):617–623.
- Ward AB, Wissel J, Borg J, et al. Functional goal achievement in post-stroke spasticity patients: the BOTOX Economic Spasticity Trial (BEST). J Rehabil Med. 2014;46(6):504–513.
- Pandyan AD, Gregoric M, Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1-2):2–6.
- Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. 2015;262(10):2201–2213.